US5869079A
(en)
*
|
1995-06-02 |
1999-02-09 |
Oculex Pharmaceuticals, Inc. |
Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
|
US6369116B1
(en)
*
|
1995-06-02 |
2002-04-09 |
Oculex Pharmaceuticals, Inc. |
Composition and method for treating glaucoma
|
KR100441821B1
(ko)
*
|
1996-03-05 |
2004-10-15 |
구르뉘 로베르 |
완충화된오르토에스테르중합체를함유하는약학조성물
|
FR2748205A1
(fr)
*
|
1996-05-06 |
1997-11-07 |
Debio Rech Pharma Sa |
Compositions pharmaceutiques pour la liberation controlee de principes actifs insolubles
|
US5942508A
(en)
*
|
1997-02-04 |
1999-08-24 |
Senju Pharmaceutical Co., Ltd. |
Method for solubilizing pyridonecarboxylic acid solubilizer thereof and aqueous solution containing solubilized pyridonecarboxylic acid
|
CA2300154C
(en)
*
|
1997-08-11 |
2008-07-08 |
Allergan Sales, Inc. |
Sterile bioerodible implant device with improved biocompatability and method
|
US7399480B2
(en)
*
|
1997-09-26 |
2008-07-15 |
Abbott Laboratories |
Methods of administering tetrazole-containing rapamycin analogs with other therapeutic substances using medical devices
|
US6890546B2
(en)
*
|
1998-09-24 |
2005-05-10 |
Abbott Laboratories |
Medical devices containing rapamycin analogs
|
US20030129215A1
(en)
*
|
1998-09-24 |
2003-07-10 |
T-Ram, Inc. |
Medical devices containing rapamycin analogs
|
US7445792B2
(en)
*
|
2003-03-10 |
2008-11-04 |
Abbott Laboratories |
Medical device having a hydration inhibitor
|
DE19756314C2
(de)
*
|
1997-12-12 |
2000-06-29 |
Roland Bodmeier |
Zubereitung mit verlängerter Verweildauer am Applikationsort
|
EP0985413A1
(de)
*
|
1998-08-06 |
2000-03-15 |
Jörg Michael Dr. Dr. Schierholz |
Medizinprodukte mit retardierter pharmakologischer Aktivität und Verfahren zu ihrer Herstellung
|
US6641831B1
(en)
|
1998-08-06 |
2003-11-04 |
Schierholz Joerg |
Medical products with sustained pharmacological activity and process for producing them
|
US7455853B2
(en)
*
|
1998-09-24 |
2008-11-25 |
Abbott Cardiovascular Systems Inc. |
Medical devices containing rapamycin analogs
|
FR2770134B1
(fr)
*
|
1998-10-28 |
2002-06-07 |
Delab |
Formulations solides ou semi-solides pour administration locale
|
CA2358296A1
(en)
*
|
1999-01-05 |
2000-07-13 |
Anthony P. Adamis |
Targeted transscleral controlled release drug delivery to the retina and choroid
|
US6113638A
(en)
*
|
1999-02-26 |
2000-09-05 |
Williams; Lytton A. |
Method and apparatus for intervertebral implant anchorage
|
US6331313B1
(en)
*
|
1999-10-22 |
2001-12-18 |
Oculex Pharmaceticals, Inc. |
Controlled-release biocompatible ocular drug delivery implant devices and methods
|
US20010049422A1
(en)
*
|
2000-04-14 |
2001-12-06 |
Phaneuf Matthew D. |
Methods of applying antibiotic compounds to polyurethane biomaterials using textile dyeing technology
|
US7708711B2
(en)
*
|
2000-04-14 |
2010-05-04 |
Glaukos Corporation |
Ocular implant with therapeutic agents and methods thereof
|
US20040033241A1
(en)
*
|
2000-06-02 |
2004-02-19 |
Allergan, Inc. |
Controlled release botulinum toxin system
|
US6692759B1
(en)
*
|
2000-06-28 |
2004-02-17 |
The Regents Of The University Of California |
Methods for preparing and using implantable substance delivery devices
|
EP3167872B1
(en)
|
2000-07-05 |
2020-10-14 |
Allergan, Inc. |
Methods for treating inflammation-mediated conditions of the eye
|
US6726918B1
(en)
*
|
2000-07-05 |
2004-04-27 |
Oculex Pharmaceuticals, Inc. |
Methods for treating inflammation-mediated conditions of the eye
|
PE20020146A1
(es)
*
|
2000-07-13 |
2002-03-31 |
Upjohn Co |
Formulacion oftalmica que comprende un inhibidor de ciclooxigenasa-2 (cox-2)
|
AR031135A1
(es)
|
2000-10-10 |
2003-09-10 |
Upjohn Co |
Composiciones de antibiotico topico para el tratamiento de infecciones oculares
|
US20030082183A1
(en)
*
|
2000-11-01 |
2003-05-01 |
Wheeler Larry A. |
Methods and compositions for treatment of ocular neovascularization and neural injury
|
WO2002058730A2
(en)
*
|
2000-11-01 |
2002-08-01 |
Allergan, Inc. |
Compositions for treatment of ocular neovascularization
|
EP1621219A3
(en)
*
|
2000-11-29 |
2006-03-22 |
Allergan, Inc. |
Intraocular implants for preventing transplant rejection in the eye
|
DE60114229T2
(de)
*
|
2000-11-29 |
2006-07-06 |
Allergan, Inc., Irvine |
Verhinderung von transplantatabstossung im auge
|
KR100446101B1
(ko)
*
|
2000-12-07 |
2004-08-30 |
주식회사 삼양사 |
수난용성 약물의 서방성 제형 조성물
|
US20020082678A1
(en)
*
|
2000-12-22 |
2002-06-27 |
Motasim Sirhan |
Intravascular delivery of mizoribine
|
ATE359762T1
(de)
*
|
2001-01-09 |
2007-05-15 |
Microchips Inc |
Flexible mikrochip-vorrichtungen zur ophthalmologischen und anderen applikation
|
US7431710B2
(en)
|
2002-04-08 |
2008-10-07 |
Glaukos Corporation |
Ocular implants with anchors and methods thereof
|
EP1387671A1
(en)
|
2001-05-03 |
2004-02-11 |
MASSACHUSETTS EYE & EAR INFIRMARY |
Implantable drug delivery device and use thereof
|
US7592016B2
(en)
*
|
2001-06-28 |
2009-09-22 |
Regents Of The University Of California |
Methods for preparing and using implantable substance delivery devices
|
GB0116920D0
(en)
*
|
2001-07-11 |
2001-09-05 |
Sulzer Vascutek Ltd |
Delivery system
|
US20080145402A1
(en)
*
|
2001-09-10 |
2008-06-19 |
Abbott Cardiovascular Systems Inc. |
Medical Devices Containing Rapamycin Analogs
|
KR20100102749A
(ko)
*
|
2002-02-22 |
2010-09-24 |
산텐 세이야꾸 가부시키가이샤 |
미립자 결막하 투여를 위한 약물 수송 시스템
|
US20030180294A1
(en)
*
|
2002-02-22 |
2003-09-25 |
Devries Gerald W. |
Methods of extending corneal graft survival
|
KR101127502B1
(ko)
*
|
2002-03-11 |
2012-03-23 |
알콘, 인코퍼레이티드 |
이식 가능한 약물 전달 시스템
|
US7074426B2
(en)
*
|
2002-03-27 |
2006-07-11 |
Frank Kochinke |
Methods and drug delivery systems for the treatment of orofacial diseases
|
AU2003217531A1
(en)
*
|
2002-05-02 |
2003-11-17 |
Massachusetts Eye And Ear Infirmary |
Ocular drug delivery systems and use thereof
|
WO2003096991A2
(en)
|
2002-05-17 |
2003-11-27 |
Othera Pharmaceuticals, Inc. |
Amelioration of the development of cataracts and other opthalmic diseases
|
JP4773721B2
(ja)
*
|
2002-06-13 |
2011-09-14 |
ノバルティス アーゲー |
第四級化アンモニウムシクロデキストリン化合物
|
EP1521573B1
(en)
*
|
2002-07-15 |
2008-01-02 |
Alcon, Inc. |
Non-polymeric lipophilic pharmaceutical implant compositions for intraocular use
|
US20070184089A1
(en)
*
|
2002-07-15 |
2007-08-09 |
Alcon, Inc. |
Non-Polymeric Lipophilic Pharmaceutical Implant Compositions for Intraocular Use
|
DE10238310A1
(de)
*
|
2002-08-21 |
2004-03-04 |
Erich Jaeger Gmbh |
Elektrodenanordnung
|
CZ294328B6
(cs)
*
|
2002-08-22 |
2004-11-10 |
Pliva-Lachema A. S. |
Biodegradabilní kompozice s prolongovaným uvolňováním biologicky aktivní látky a způsob její výroby
|
WO2004022124A1
(en)
*
|
2002-09-06 |
2004-03-18 |
Abbott Laboratories |
Medical device having hydration inhibitor
|
CA2689424A1
(en)
*
|
2002-09-29 |
2004-04-08 |
Surmodics, Inc. |
Methods for treatment and/or prevention of retinal disease
|
AU2003301347A1
(en)
*
|
2002-10-17 |
2004-05-04 |
Control Delivery Systems, Inc. |
Methods for monitoring treatment of disease
|
AU2003284028B2
(en)
*
|
2002-10-17 |
2007-05-10 |
Alkermes, Inc. |
Sustained release profile modification
|
JP2004196787A
(ja)
*
|
2002-12-04 |
2004-07-15 |
Santen Pharmaceut Co Ltd |
結膜下デポによるドラッグデリバリーシステム
|
CN100453066C
(zh)
*
|
2002-12-04 |
2009-01-21 |
参天制药株式会社 |
利用结膜下储存库的药物释放系统
|
US20050048099A1
(en)
|
2003-01-09 |
2005-03-03 |
Allergan, Inc. |
Ocular implant made by a double extrusion process
|
US20040137059A1
(en)
*
|
2003-01-09 |
2004-07-15 |
Thierry Nivaggioli |
Biodegradable ocular implant
|
EP1594484A2
(en)
*
|
2003-02-17 |
2005-11-16 |
Cipla Ltd. |
Pharmaceutical patch
|
WO2004073551A2
(en)
*
|
2003-02-18 |
2004-09-02 |
Massachusetts Eye And Ear Infirmary |
Transscleral drug delivery device and related methods
|
US8012115B2
(en)
*
|
2003-02-18 |
2011-09-06 |
S.K. Pharmaceuticals, Inc. |
Optic nerve implants
|
CN1750828A
(zh)
*
|
2003-02-20 |
2006-03-22 |
爱尔康公司 |
类固醇治疗眼病患者的用途
|
US20040167109A1
(en)
*
|
2003-02-20 |
2004-08-26 |
Bingaman David P |
Formulations of glucocorticoids to treat pathologic ocular angiogenesis
|
US7825134B2
(en)
*
|
2003-05-19 |
2010-11-02 |
Othera Holding, Inc. |
Amelioration of cataracts, macular degeneration and other ophthalmic diseases
|
US7589107B2
(en)
|
2003-05-19 |
2009-09-15 |
Othera Holding, Inc. |
Amelioration of vitrectomy-induced cataracts
|
RU2006101150A
(ru)
*
|
2003-06-13 |
2006-06-10 |
Алькон, Инк. (Ch) |
Композиции нестероидных противовоспалительных средств для лечения патологического ангиогенеза глаз
|
US20040253293A1
(en)
*
|
2003-06-16 |
2004-12-16 |
Afshin Shafiee |
Rate controlled release of a pharmaceutical agent in a biodegradable device
|
EP1641914B1
(en)
*
|
2003-06-27 |
2016-07-20 |
DePuy Synthes Products, Inc. |
Postpartum cells derived from placental tissue, and methods of making and using the same
|
US9592258B2
(en)
|
2003-06-27 |
2017-03-14 |
DePuy Synthes Products, Inc. |
Treatment of neurological injury by administration of human umbilical cord tissue-derived cells
|
US8790637B2
(en)
*
|
2003-06-27 |
2014-07-29 |
DePuy Synthes Products, LLC |
Repair and regeneration of ocular tissue using postpartum-derived cells
|
US8518390B2
(en)
|
2003-06-27 |
2013-08-27 |
Advanced Technologies And Regenerative Medicine, Llc |
Treatment of stroke and other acute neural degenerative disorders via intranasal administration of umbilical cord-derived cells
|
US8491883B2
(en)
*
|
2003-06-27 |
2013-07-23 |
Advanced Technologies And Regenerative Medicine, Llc |
Treatment of amyotrophic lateral sclerosis using umbilical derived cells
|
US20060223177A1
(en)
|
2003-06-27 |
2006-10-05 |
Ethicon Inc. |
Postpartum cells derived from umbilical cord tissue, and methods of making and using the same
|
US7875272B2
(en)
|
2003-06-27 |
2011-01-25 |
Ethicon, Incorporated |
Treatment of stroke and other acute neuraldegenerative disorders using postpartum derived cells
|
US20100158880A1
(en)
*
|
2008-12-19 |
2010-06-24 |
Ethicon, Incorporated |
Regeneration and repair of neural tissue following injury
|
US9572840B2
(en)
|
2003-06-27 |
2017-02-21 |
DePuy Synthes Products, Inc. |
Regeneration and repair of neural tissue using postpartum-derived cells
|
CN1835735B
(zh)
*
|
2003-08-20 |
2010-05-12 |
参天制药株式会社 |
微粒眼球筋膜下给药的药物释放系统
|
WO2005037317A2
(en)
*
|
2003-10-17 |
2005-04-28 |
Cornell Research Foundation, Inc. |
Mast cell-derived renin
|
US20070224278A1
(en)
*
|
2003-11-12 |
2007-09-27 |
Lyons Robert T |
Low immunogenicity corticosteroid compositions
|
US20060141049A1
(en)
*
|
2003-11-12 |
2006-06-29 |
Allergan, Inc. |
Triamcinolone compositions for intravitreal administration to treat ocular conditions
|
US20050101582A1
(en)
|
2003-11-12 |
2005-05-12 |
Allergan, Inc. |
Compositions and methods for treating a posterior segment of an eye
|
US20090148527A1
(en)
*
|
2007-12-07 |
2009-06-11 |
Robinson Michael R |
Intraocular formulation
|
EP2052720A3
(en)
|
2003-11-20 |
2009-05-06 |
Othera Holding, Inc. |
Use of at least one hydroxylamine compound for the treatment of eye disease
|
US20080220049A1
(en)
*
|
2003-12-05 |
2008-09-11 |
Adnexus, A Bristol-Myers Squibb R&D Company |
Compositions and methods for intraocular delivery of fibronectin scaffold domain proteins
|
RU2402567C2
(ru)
|
2003-12-05 |
2010-10-27 |
Бристоль-Майерз Сквибб Компани |
Ингибиторы рецепторов фактора роста эндотелия сосудов типа 2
|
WO2005061003A1
(en)
*
|
2003-12-12 |
2005-07-07 |
Medtronic, Inc. |
Anti-infective medical device
|
US8691258B2
(en)
*
|
2003-12-12 |
2014-04-08 |
Medtronic, Inc. |
Anti-infective medical device
|
WO2005072701A1
(en)
|
2004-01-20 |
2005-08-11 |
Allergan, Inc. |
Compositions for localized therapy of the eye, comprising preferably triamcinolone acetonide and hyaluronic acid
|
US8119154B2
(en)
|
2004-04-30 |
2012-02-21 |
Allergan, Inc. |
Sustained release intraocular implants and related methods
|
US20050244463A1
(en)
|
2004-04-30 |
2005-11-03 |
Allergan, Inc. |
Sustained release intraocular implants and methods for treating ocular vasculopathies
|
US8591885B2
(en)
*
|
2004-04-30 |
2013-11-26 |
Allergan, Inc. |
Carbonic anhydrase inhibitor sustained release intraocular drug delivery systems
|
US7589057B2
(en)
|
2004-04-30 |
2009-09-15 |
Allergan, Inc. |
Oil-in-water method for making alpha-2 agonist polymeric drug delivery systems
|
US20070059336A1
(en)
*
|
2004-04-30 |
2007-03-15 |
Allergan, Inc. |
Anti-angiogenic sustained release intraocular implants and related methods
|
US20050244478A1
(en)
*
|
2004-04-30 |
2005-11-03 |
Allergan, Inc. |
Anti-excititoxic sustained release intraocular implants and related methods
|
US20060182781A1
(en)
*
|
2004-04-30 |
2006-08-17 |
Allergan, Inc. |
Methods for treating ocular conditions with cyclic lipid contraining microparticles
|
US20050244500A1
(en)
*
|
2004-04-30 |
2005-11-03 |
Allergan, Inc. |
Intravitreal implants in conjuction with photodynamic therapy to improve vision
|
US8722097B2
(en)
|
2004-04-30 |
2014-05-13 |
Allergan, Inc. |
Oil-in-water method for making polymeric implants containing a hypotensive lipid
|
US7771742B2
(en)
*
|
2004-04-30 |
2010-08-10 |
Allergan, Inc. |
Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods
|
US8673341B2
(en)
|
2004-04-30 |
2014-03-18 |
Allergan, Inc. |
Intraocular pressure reduction with intracameral bimatoprost implants
|
US20050244462A1
(en)
*
|
2004-04-30 |
2005-11-03 |
Allergan, Inc. |
Devices and methods for treating a mammalian eye
|
WO2005110374A1
(en)
|
2004-04-30 |
2005-11-24 |
Allergan, Inc. |
Intraocular drug delivery systems containing a therapeutic component, a cyclodextrin, and a polymeric component
|
US8529927B2
(en)
*
|
2004-04-30 |
2013-09-10 |
Allergan, Inc. |
Alpha-2 agonist polymeric drug delivery systems
|
WO2005107708A1
(en)
|
2004-04-30 |
2005-11-17 |
Allergan, Inc. |
Biodegradable intravitreal tyrosine kinase inhibitors implants
|
US20050244458A1
(en)
*
|
2004-04-30 |
2005-11-03 |
Allergan, Inc. |
Sustained release intraocular implants and methods for treating ocular neuropathies
|
US7993634B2
(en)
|
2004-04-30 |
2011-08-09 |
Allergan, Inc. |
Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods
|
US8685435B2
(en)
*
|
2004-04-30 |
2014-04-01 |
Allergan, Inc. |
Extended release biodegradable ocular implants
|
US20050244471A1
(en)
*
|
2004-04-30 |
2005-11-03 |
Allergan, Inc. |
Estradiol derivative and estratopone containing sustained release intraocular implants and related methods
|
US20050244465A1
(en)
*
|
2004-04-30 |
2005-11-03 |
Allergan, Inc. |
Drug delivery systems and methods for treatment of an eye
|
US20070212395A1
(en)
*
|
2006-03-08 |
2007-09-13 |
Allergan, Inc. |
Ocular therapy using sirtuin-activating agents
|
US8425929B2
(en)
*
|
2004-04-30 |
2013-04-23 |
Allergan, Inc. |
Sustained release intraocular implants and methods for preventing retinal dysfunction
|
US20050244461A1
(en)
*
|
2004-04-30 |
2005-11-03 |
Allergan, Inc. |
Controlled release drug delivery systems and methods for treatment of an eye
|
US20050244466A1
(en)
*
|
2004-04-30 |
2005-11-03 |
Allergan, Inc. |
Photodynamic therapy in conjunction with intraocular implants
|
US20060182783A1
(en)
*
|
2004-04-30 |
2006-08-17 |
Allergan, Inc. |
Sustained release intraocular drug delivery systems
|
US8147865B2
(en)
*
|
2004-04-30 |
2012-04-03 |
Allergan, Inc. |
Steroid-containing sustained release intraocular implants and related methods
|
US9498457B2
(en)
|
2004-04-30 |
2016-11-22 |
Allergan, Inc. |
Hypotensive prostamide-containing biodegradable intraocular implants and related implants
|
AU2011213904B2
(en)
*
|
2004-04-30 |
2014-06-05 |
Allergan, Inc. |
Sustained release intraocular implants comprising a beta adrenergic receptor antagonist and methods for treating ocular neuropathies
|
US7799336B2
(en)
|
2004-04-30 |
2010-09-21 |
Allergan, Inc. |
Hypotensive lipid-containing biodegradable intraocular implants and related methods
|
US20050244469A1
(en)
*
|
2004-04-30 |
2005-11-03 |
Allergan, Inc. |
Extended therapeutic effect ocular implant treatments
|
CN1964711A
(zh)
*
|
2004-05-25 |
2007-05-16 |
奥特拉药物公司 |
眼睛选择性药物及前体药物
|
WO2006014484A2
(en)
|
2004-07-02 |
2006-02-09 |
Surmodics, Inc. |
Methods and devices for the treatment of ocular conditions
|
AU2013221985B2
(en)
*
|
2004-07-12 |
2016-09-01 |
Allergan, Inc. |
Ophthalmic compositions and methods for treating ophthalmic conditions
|
JP2008505978A
(ja)
*
|
2004-07-12 |
2008-02-28 |
アラーガン、インコーポレイテッド |
眼病用組成物および眼病治療法
|
WO2006078320A2
(en)
|
2004-08-04 |
2006-07-27 |
Brookwood Pharmaceuticals, Inc. |
Methods for manufacturing delivery devices and devices thereof
|
US20160106717A1
(en)
|
2004-09-24 |
2016-04-21 |
Gen Pharma Holdings LLC |
Cai-based systems and methods for the localized treatment of uveitis
|
US20060116404A1
(en)
|
2004-09-24 |
2006-06-01 |
Gary Robinson |
CAI-based systems and methods for the localized treatment of ocular and other diseases
|
US20060067978A1
(en)
*
|
2004-09-29 |
2006-03-30 |
Bausch & Lomb Incorporated |
Process for preparing poly(vinyl alcohol) drug delivery devices
|
US20060068012A1
(en)
*
|
2004-09-29 |
2006-03-30 |
Bausch & Lomb Incorporated |
Process for preparing poly (vinyl alcohol) drug delivery devices with humidity control
|
JP5682991B2
(ja)
|
2004-10-01 |
2015-03-11 |
ラムズコア, インコーポレイテッド |
便利に移植可能な徐放性薬物処方物
|
US8541413B2
(en)
*
|
2004-10-01 |
2013-09-24 |
Ramscor, Inc. |
Sustained release eye drop formulations
|
US20080038316A1
(en)
*
|
2004-10-01 |
2008-02-14 |
Wong Vernon G |
Conveniently implantable sustained release drug compositions
|
US9993558B2
(en)
|
2004-10-01 |
2018-06-12 |
Ramscor, Inc. |
Sustained release eye drop formulations
|
WO2006043965A1
(en)
*
|
2004-10-14 |
2006-04-27 |
Allergan, Inc. |
Therapeutic ophthalmic compositions containing retinal friendly excipients and related methods
|
KR20070095921A
(ko)
|
2004-12-10 |
2007-10-01 |
탈리마 테라퓨틱스 인코포레이티드 |
조갑 단위의 상태를 치료하기 위한 조성물 및 방법
|
US20060275230A1
(en)
|
2004-12-10 |
2006-12-07 |
Frank Kochinke |
Compositions and methods for treating conditions of the nail unit
|
US20060166361A1
(en)
*
|
2004-12-21 |
2006-07-27 |
Agnieszka Seyda |
Postpartum cells derived from placental tissue, and methods of making, culturing, and using the same
|
US20060153815A1
(en)
*
|
2004-12-21 |
2006-07-13 |
Agnieszka Seyda |
Tissue engineering devices for the repair and regeneration of tissue
|
US20060171930A1
(en)
*
|
2004-12-21 |
2006-08-03 |
Agnieszka Seyda |
Postpartum cells derived from umbilical cord tissue, and methods of making, culturing, and using the same
|
US20060134174A1
(en)
*
|
2004-12-22 |
2006-06-22 |
Bausch & Lomb Incorporated |
Pharmaceutical delivery system and method of use
|
US20060134175A1
(en)
*
|
2004-12-22 |
2006-06-22 |
Stephen Bartels |
Drug eluting pharmaceutical delivery system for treatment of ocular disease and method of use
|
WO2006071802A2
(en)
|
2004-12-23 |
2006-07-06 |
Ethicon Incorporated |
Treatment of stroke and other acute neural degenerative disorders using postpartum derived cells
|
US20060165810A1
(en)
*
|
2004-12-28 |
2006-07-27 |
The Trustees Of The University Of Pennsylvania |
Controlled release from block co-polymer worm micelles
|
US20060204548A1
(en)
*
|
2005-03-01 |
2006-09-14 |
Allergan, Inc. |
Microimplants for ocular administration
|
US20060233858A1
(en)
*
|
2005-03-08 |
2006-10-19 |
Allergan, Inc. |
Systems and methods providing targeted intraocular drug delivery
|
US8003124B2
(en)
*
|
2005-04-08 |
2011-08-23 |
Surmodics, Inc. |
Sustained release implants and methods for subretinal delivery of bioactive agents to treat or prevent retinal disease
|
US7931909B2
(en)
*
|
2005-05-10 |
2011-04-26 |
Allergan, Inc. |
Ocular therapy using alpha-2 adrenergic receptor compounds having enhanced anterior clearance rates
|
WO2006127592A2
(en)
*
|
2005-05-26 |
2006-11-30 |
Othera Pharmaceuticals, Inc. |
Use of hydroxylamine derivates for inhibiting vitrectomy-induced cataracts
|
AU2006272497B2
(en)
|
2005-07-27 |
2012-07-19 |
University Of Florida Research Foundation, Inc. |
Small compounds that correct protein misfolding and uses thereof
|
WO2007037849A2
(en)
*
|
2005-09-16 |
2007-04-05 |
Allergan, Inc. |
Compositions and methods for the intraocular transport of therapeutic agents
|
JP2009510114A
(ja)
|
2005-09-30 |
2009-03-12 |
ビテ ファーマシューティカルズ, インコーポレイテッド |
特定のrxrアゴニストによる癌治療
|
US8168584B2
(en)
|
2005-10-08 |
2012-05-01 |
Potentia Pharmaceuticals, Inc. |
Methods of treating age-related macular degeneration by compstatin and analogs thereof
|
WO2007047626A1
(en)
*
|
2005-10-14 |
2007-04-26 |
Alcon, Inc. |
Combination treatment with anecortave acetate and bevacizumab or ranibizumab for pathologic ocular angiogenesis
|
JP5745208B2
(ja)
*
|
2005-10-18 |
2015-07-08 |
アラーガン インコーポレイテッドAllergan,Incorporated |
後区組織に選択的に浸透するグルココルチコイド誘導体を用いた眼治療
|
SI1968594T1
(sl)
|
2005-11-29 |
2011-01-31 |
Glaxosmithkline Llc |
Tretma okularnih neovaskularnih motenj, kot makularne degeneracije, angiodnih prog. uveitisa in makularnega edema
|
PL1971681T3
(pl)
*
|
2005-12-16 |
2018-01-31 |
Depuy Synthes Products Inc |
Kompozycje oraz sposoby do hamowania niepożądanej odpowiedzi immunologicznej w przypadku transplantacji z brakiem zgodności tkankowej
|
JP5179376B2
(ja)
*
|
2005-12-19 |
2013-04-10 |
エシコン・インコーポレイテッド |
ローラーボトルでの分娩後取り出し細胞の体外増殖
|
US20070160588A1
(en)
*
|
2005-12-28 |
2007-07-12 |
Ethicon, Incorporated |
Treatment Of Peripheral Vascular Disease Using Postpartum-Derived Cells
|
US9125906B2
(en)
|
2005-12-28 |
2015-09-08 |
DePuy Synthes Products, Inc. |
Treatment of peripheral vascular disease using umbilical cord tissue-derived cells
|
US7756524B1
(en)
|
2006-01-31 |
2010-07-13 |
Nextel Communications Inc. |
System and method for partially count-based allocation of vocoder resources
|
US20070178138A1
(en)
*
|
2006-02-01 |
2007-08-02 |
Allergan, Inc. |
Biodegradable non-opthalmic implants and related methods
|
EP1993584B1
(en)
|
2006-02-02 |
2012-05-30 |
Allergan, Inc. |
Inhibitors of CXCR4 activity for use in the treatment of ocular disorders
|
US20070203190A1
(en)
*
|
2006-02-22 |
2007-08-30 |
Ghanshyam Patil |
Hydroxylamines and derivatives for the inhibition of complement activation
|
US20070232660A1
(en)
*
|
2006-04-04 |
2007-10-04 |
Allergan, Inc. |
Therapeutic and delivery methods of prostaglandin ep4 agonists
|
US20070260203A1
(en)
*
|
2006-05-04 |
2007-11-08 |
Allergan, Inc. |
Vasoactive agent intraocular implant
|
US8668676B2
(en)
*
|
2006-06-19 |
2014-03-11 |
Allergan, Inc. |
Apparatus and methods for implanting particulate ocular implants
|
US8802128B2
(en)
*
|
2006-06-23 |
2014-08-12 |
Allergan, Inc. |
Steroid-containing sustained release intraocular implants and related methods
|
US20070298073A1
(en)
*
|
2006-06-23 |
2007-12-27 |
Allergan, Inc. |
Steroid-containing sustained release intraocular implants and related methods
|
US20080097335A1
(en)
*
|
2006-08-04 |
2008-04-24 |
Allergan, Inc. |
Ocular implant delivery assemblies
|
JP5694664B2
(ja)
*
|
2006-09-29 |
2015-04-01 |
サーモディクス,インコーポレイティド |
生分解性眼用インプラント及び眼の病気を治療する方法
|
CA2667890C
(en)
|
2006-10-31 |
2015-01-27 |
Surmodics Pharmaceuticals, Inc. |
Spheronized polymer particles
|
US8039010B2
(en)
|
2006-11-03 |
2011-10-18 |
Allergan, Inc. |
Sustained release intraocular drug delivery systems comprising a water soluble therapeutic agent and a release modifier
|
US8586556B2
(en)
*
|
2006-11-03 |
2013-11-19 |
Allergan, Inc. |
Methods, compositions and drug delivery systems for intraocular delivery of siRNA molecules
|
EP3156415A1
(en)
|
2006-11-22 |
2017-04-19 |
Bristol-Myers Squibb Company |
Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including igf-ir
|
US8969415B2
(en)
*
|
2006-12-01 |
2015-03-03 |
Allergan, Inc. |
Intraocular drug delivery systems
|
WO2008070479A2
(en)
|
2006-12-01 |
2008-06-12 |
Allergan, Inc. |
Method for determining optimum intraocular locations for drug delivery systems
|
US8846073B2
(en)
|
2006-12-19 |
2014-09-30 |
Allergan, Inc. |
Low temperature processes for making cyclic lipid implants for intraocular use
|
US20090092574A1
(en)
|
2006-12-29 |
2009-04-09 |
Scott Richard W |
Ophthalmic And Otic Compositions Of Facially Amphiphilic Polymers And Oligomers And Uses Thereof
|
CA2679066A1
(en)
|
2007-02-22 |
2008-08-28 |
Othera Holding, Inc. |
Hydroxylamine compounds and methods of their use
|
US7911053B2
(en)
*
|
2007-04-19 |
2011-03-22 |
Marvell World Trade Ltd. |
Semiconductor packaging with internal wiring bus
|
AU2008254989B2
(en)
*
|
2007-05-14 |
2013-06-06 |
Sustained Nano Systems Llc |
Hypercompressed particles for controlled release of ophthalmic medications
|
US8231892B2
(en)
*
|
2007-05-24 |
2012-07-31 |
Allergan, Inc. |
Biodegradable drug delivery system
|
US20080317805A1
(en)
*
|
2007-06-19 |
2008-12-25 |
Mckay William F |
Locally administrated low doses of corticosteroids
|
WO2009029543A1
(en)
|
2007-08-24 |
2009-03-05 |
Aegis Therapeutics, Llc |
Controlled release formulations
|
WO2009046299A2
(en)
*
|
2007-10-04 |
2009-04-09 |
Boston Scientific Scimed, Inc |
Implantable drug depot for intrathecal drug delivery system for pain management
|
AU2008308531B2
(en)
*
|
2007-10-05 |
2014-04-24 |
Ethicon, Incorporated |
Repair and regeneration of renal tissue using human umbilical cord tissue-derived cells
|
CN101918019B
(zh)
|
2007-10-08 |
2014-11-26 |
奥里尼亚制药有限公司 |
包含钙调神经磷酸酶抑制剂或mTOR抑制剂的眼科组合物
|
US8124601B2
(en)
*
|
2007-11-21 |
2012-02-28 |
Bristol-Myers Squibb Company |
Compounds for the treatment of Hepatitis C
|
US8236538B2
(en)
|
2007-12-20 |
2012-08-07 |
Advanced Technologies And Regenerative Medicine, Llc |
Methods for sterilizing materials containing biologically active agents
|
WO2009085952A1
(en)
|
2007-12-20 |
2009-07-09 |
Brookwood Pharmaceuticals, Inc. |
Process for preparing microparticles having a low residual solvent volume
|
KR20100128291A
(ko)
|
2008-02-14 |
2010-12-07 |
브리스톨-마이어스 스큅 컴퍼니 |
Egfr에 결합하는 조작된 단백질을 기초로 하는 표적화된 치료제
|
US9192571B2
(en)
|
2008-03-03 |
2015-11-24 |
Allergan, Inc. |
Ketorolac tromethamine compositions for treating or preventing ocular pain
|
US8524267B2
(en)
*
|
2008-04-18 |
2013-09-03 |
Warsaw Orthopedic, Inc. |
Dexamethasone formulations in a biodegradable material
|
US9095404B2
(en)
|
2008-05-12 |
2015-08-04 |
University Of Utah Research Foundation |
Intraocular drug delivery device and associated methods
|
US9877973B2
(en)
|
2008-05-12 |
2018-01-30 |
University Of Utah Research Foundation |
Intraocular drug delivery device and associated methods
|
WO2009140246A2
(en)
|
2008-05-12 |
2009-11-19 |
University Of Utah Research Foundation |
Intraocular drug delivery device and associated methods
|
US10064819B2
(en)
|
2008-05-12 |
2018-09-04 |
University Of Utah Research Foundation |
Intraocular drug delivery device and associated methods
|
US10588855B2
(en)
|
2008-05-12 |
2020-03-17 |
University Of Utah Research Foundation |
Intraocular drug delivery device and associated methods
|
JP2011520961A
(ja)
|
2008-05-22 |
2011-07-21 |
ブリストル−マイヤーズ スクイブ カンパニー |
多価フィブロネクチンをベースとする足場ドメインタンパク質
|
US10517839B2
(en)
*
|
2008-06-09 |
2019-12-31 |
Cornell University |
Mast cell inhibition in diseases of the retina and vitreous
|
US8821870B2
(en)
*
|
2008-07-18 |
2014-09-02 |
Allergan, Inc. |
Method for treating atrophic age related macular degeneration
|
PT2320911E
(pt)
|
2008-08-01 |
2014-11-11 |
Eye Therapies Llc |
Composições de vasoconstrição e métodos de utilização
|
WO2010036961A1
(en)
*
|
2008-09-25 |
2010-04-01 |
Invivo Therapeutics Corporation |
Spinal cord injury, inflammation, and immune-disease: local controlled release of therapeutic agents
|
US20100104654A1
(en)
|
2008-10-27 |
2010-04-29 |
Allergan, Inc. |
Prostaglandin and prostamide drug delivery systems and intraocular therapeutic uses thereof
|
US9095506B2
(en)
|
2008-11-17 |
2015-08-04 |
Allergan, Inc. |
Biodegradable alpha-2 agonist polymeric implants and therapeutic uses thereof
|
US8034813B2
(en)
|
2008-11-18 |
2011-10-11 |
Bausch & Lomb Incorporated |
Polymorphs of brimonidine pamoate
|
TWI496582B
(zh)
|
2008-11-24 |
2015-08-21 |
必治妥美雅史谷比公司 |
雙重專一性之egfr/igfir結合分子
|
ES2520393T3
(es)
*
|
2008-12-19 |
2014-11-11 |
DePuy Synthes Products, LLC |
Células derivadas de tejido del cordón umbilical para tratar dolor neuropático y espasticidad
|
US10179900B2
(en)
*
|
2008-12-19 |
2019-01-15 |
DePuy Synthes Products, Inc. |
Conditioned media and methods of making a conditioned media
|
AU2009327384B2
(en)
|
2008-12-19 |
2014-07-10 |
DePuy Synthes Products, LLC |
Treatment of lung and pulmonary diseases and disorders
|
US8545554B2
(en)
*
|
2009-01-16 |
2013-10-01 |
Allergan, Inc. |
Intraocular injector
|
US20100291182A1
(en)
*
|
2009-01-21 |
2010-11-18 |
Arsenal Medical, Inc. |
Drug-Loaded Fibers
|
US20100204325A1
(en)
*
|
2009-02-11 |
2010-08-12 |
Allergan, Inc. |
Valproic acid drug delivery systems and intraocular therapeutic uses thereof
|
US9636255B2
(en)
|
2009-02-13 |
2017-05-02 |
Dose Medical Corporation |
Uveoscleral drug delivery implant and methods for implanting the same
|
US20100239632A1
(en)
*
|
2009-03-23 |
2010-09-23 |
Warsaw Orthopedic, Inc. |
Drug depots for treatment of pain and inflammation in sinus and nasal cavities or cardiac tissue
|
CN102498204B
(zh)
|
2009-03-26 |
2015-02-04 |
德普伊新特斯产品有限责任公司 |
人脐带组织细胞作为用于阿尔茨海默病的疗法
|
US10206813B2
(en)
|
2009-05-18 |
2019-02-19 |
Dose Medical Corporation |
Implants with controlled drug delivery features and methods of using same
|
AU2010259184B2
(en)
*
|
2009-06-09 |
2015-08-13 |
Aurinia Pharmaceuticals Inc. |
Topical drug delivery systems for ophthalmic use
|
IN2012DN00352A
(da)
|
2009-06-16 |
2015-08-21 |
Bikam Pharmaceuticals Inc |
|
GB201111485D0
(en)
|
2011-07-05 |
2011-08-17 |
Biocopea Ltd |
Drug composition and its use in therapy
|
WO2010148352A1
(en)
|
2009-06-19 |
2010-12-23 |
Altos Vision Limited |
Time-release and micro-dose formulations for topical application of estrogen and estrogen analogs or other estrogen receptor modulators in the treatment of dry eye syndrome, and methods of preparation and application
|
JP2013501033A
(ja)
*
|
2009-08-05 |
2013-01-10 |
ピエリス アーゲー |
リポカリン突然変異タンパク質の制御放出製剤
|
US20110202016A1
(en)
*
|
2009-08-24 |
2011-08-18 |
Arsenal Medical, Inc. |
Systems and methods relating to polymer foams
|
US9173817B2
(en)
|
2009-08-24 |
2015-11-03 |
Arsenal Medical, Inc. |
In situ forming hemostatic foam implants
|
US10420862B2
(en)
|
2009-08-24 |
2019-09-24 |
Aresenal AAA, LLC. |
In-situ forming foams for treatment of aneurysms
|
US9044580B2
(en)
|
2009-08-24 |
2015-06-02 |
Arsenal Medical, Inc. |
In-situ forming foams with outer layer
|
WO2011039648A1
(en)
|
2009-09-30 |
2011-04-07 |
Glaxo Wellcome Manufacturing Pte Ltd. |
Methods of administration and treatment
|
WO2011048070A1
(en)
|
2009-10-20 |
2011-04-28 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment of disorders of glucose homeostasis
|
CN102724951A
(zh)
|
2009-11-09 |
2012-10-10 |
阿勒根公司 |
用于刺激毛发生长的组合物和方法
|
EP2512389B1
(en)
|
2009-12-16 |
2015-09-02 |
Allergan, Inc. |
Intracameral devices for sustained delivery
|
KR20180117211A
(ko)
|
2010-01-22 |
2018-10-26 |
알러간, 인코포레이티드 |
전방내 서방성 치료제 이식물
|
WO2011106697A1
(en)
|
2010-02-25 |
2011-09-01 |
Schepens Eye Research Institute |
Therapeutic compositions for the treatment of dry eye disease
|
KR20130055562A
(ko)
|
2010-03-08 |
2013-05-28 |
스펙트럼 파마슈티컬즈 인크 |
암을 치료하기 위한 티옥산톤계 자가포식작용 저해제 치료제
|
JP6327852B2
(ja)
|
2010-05-04 |
2018-05-23 |
コリウム インターナショナル, インコーポレイテッド |
微小突起アレイを使用した副甲状腺ホルモンの経皮送達のための方法及びデバイス
|
EP2977084B1
(en)
|
2010-05-10 |
2017-07-05 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for the treatment of fluid accumulation in and/ or under the retina
|
EP2576615B1
(en)
|
2010-05-26 |
2016-03-30 |
Bristol-Myers Squibb Company |
Fibronectin based scaffold proteins having improved stability
|
WO2011159824A1
(en)
|
2010-06-16 |
2011-12-22 |
Allergan, Inc. |
Composition and method for treating overactive bladder
|
CA2803923A1
(en)
|
2010-06-25 |
2011-12-29 |
Ignacio R. Rodriguez |
Methods of treatment using sterculic acid
|
EP2595602B1
(en)
|
2010-07-21 |
2018-05-23 |
Allergan, Inc. |
SUSTAINED RELEASE siRNA FOR OCULAR DRUG DELIVERY
|
EP2605762A1
(en)
|
2010-08-19 |
2013-06-26 |
Allergan, Inc. |
Compositions comprising adipose tissue and a pge2 analogue and their use in the treatment of a soft tissue condition
|
US8697057B2
(en)
|
2010-08-19 |
2014-04-15 |
Allergan, Inc. |
Compositions and soft tissue replacement methods
|
US9668915B2
(en)
|
2010-11-24 |
2017-06-06 |
Dose Medical Corporation |
Drug eluting ocular implant
|
US8349005B2
(en)
|
2011-01-03 |
2013-01-08 |
Masatoshi Murata |
Method for burying implant to choroid
|
US20140024627A1
(en)
|
2011-01-03 |
2014-01-23 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Methods and pharmaceutical compositions for the treatment of ocular inflammatory diseases
|
US8968626B2
(en)
|
2011-01-31 |
2015-03-03 |
Arsenal Medical, Inc. |
Electrospinning process for manufacture of multi-layered structures
|
US9194058B2
(en)
|
2011-01-31 |
2015-11-24 |
Arsenal Medical, Inc. |
Electrospinning process for manufacture of multi-layered structures
|
US9034240B2
(en)
|
2011-01-31 |
2015-05-19 |
Arsenal Medical, Inc. |
Electrospinning process for fiber manufacture
|
WO2012112757A2
(en)
|
2011-02-17 |
2012-08-23 |
Allergan, Inc. |
Compositions and improved soft tissue replacement methods
|
EP2678022A2
(en)
|
2011-02-23 |
2014-01-01 |
Allergan, Inc. |
Compositions and improved soft tissue replacement methods
|
CN103732218A
(zh)
|
2011-06-03 |
2014-04-16 |
阿勒根公司 |
类维生素a化合物至皮脂腺的靶向递送
|
US10245178B1
(en)
|
2011-06-07 |
2019-04-02 |
Glaukos Corporation |
Anterior chamber drug-eluting ocular implant
|
EP2720539B1
(en)
|
2011-06-14 |
2018-10-24 |
Bikam Pharmaceuticals, Inc. |
Opsin-binding ligands, compositions and methods of use
|
EP2723357A4
(en)
|
2011-06-21 |
2015-04-01 |
Bvw Holding Ag |
MEDICAL DEVICE COMPRISING BOSWELLIC ACID
|
ES2666857T3
(es)
|
2011-07-18 |
2018-05-08 |
Mor-Research Applications Ltd. |
Un dispositivo para ajustar la presión intraocular
|
AU2012325341B2
(en)
|
2011-10-19 |
2017-01-05 |
Bikam Pharmaceuticals, Inc. |
Opsin-binding ligands, compositions and methods of use
|
US8993831B2
(en)
|
2011-11-01 |
2015-03-31 |
Arsenal Medical, Inc. |
Foam and delivery system for treatment of postpartum hemorrhage
|
EP2944628B1
(en)
|
2011-11-30 |
2017-01-04 |
Bikam Pharmaceuticals, Inc. |
Opsin-binding ligands, compositions and methods of use
|
EP2785178B1
(en)
|
2011-12-01 |
2019-05-01 |
Bikam Pharmaceuticals, Inc. |
Opsin-binding ligands, compositions and methods of use
|
KR20190090048A
(ko)
|
2011-12-05 |
2019-07-31 |
인셉트, 엘엘씨 |
의료용 유기젤 방법 및 조성물
|
CN110151745A
(zh)
|
2011-12-13 |
2019-08-23 |
Io治疗公司 |
使用rxr激动剂的自身免疫紊乱的治疗
|
US10653650B2
(en)
|
2011-12-13 |
2020-05-19 |
Io Therapeutics, Inc. |
Treatment of diseases by concurrently eliciting remyelination effects and immunomodulatory effects using selective RXR agonists
|
AU2012358810B2
(en)
|
2011-12-23 |
2018-03-15 |
DePuy Synthes Products, Inc. |
Detection of human umbilical cord tissue-derived cells
|
EP2802622A4
(en)
*
|
2012-01-13 |
2015-08-26 |
Univ Missouri |
LOW TEMPERATURE PLASMA COATING FOR ANTIBIOFILM FORMATION
|
EP2814510A1
(en)
|
2012-02-16 |
2014-12-24 |
Allergan, Inc. |
Compositions and improved soft tissue replacement methods
|
EP2814526B1
(en)
|
2012-02-16 |
2016-11-02 |
Allergan, Inc. |
Compositions and improved soft tissue replacement methods
|
WO2013123275A1
(en)
|
2012-02-16 |
2013-08-22 |
Allergan, Inc. |
Compositions and improved soft tissue replacement methods
|
WO2013123270A1
(en)
|
2012-02-16 |
2013-08-22 |
Allergan, Inc. |
Compositions and improved soft tissue replacement methods
|
MX367782B
(es)
|
2012-09-26 |
2019-09-04 |
Tangent Reprofiling Ltd |
Moduladores de la sintesis de andrógenos.
|
CA2886081A1
(en)
*
|
2012-09-27 |
2014-04-03 |
Allergan, Inc. |
Biodegradable drug delivery systems for the sustained release of proteins
|
WO2014058742A1
(en)
|
2012-10-09 |
2014-04-17 |
Sears Douglas |
Therapeutic treatment
|
WO2014064191A2
(en)
|
2012-10-24 |
2014-05-01 |
Biocopea Limited |
Drug combinations and uses
|
PT3660033T
(pt)
|
2012-11-15 |
2021-07-06 |
Apellis Pharmaceuticals Inc |
Análogos de compstatina de longa ação e composições e métodos relacionados
|
JP6865524B2
(ja)
|
2012-12-21 |
2021-04-28 |
コリウム, インコーポレイテッド |
治療剤を送達するためのマイクロアレイおよび使用方法
|
JP6513576B2
(ja)
|
2013-01-14 |
2019-05-15 |
ヘルス クリニックス リミテッド |
抗がん剤および使用
|
NZ710444A
(en)
|
2013-02-11 |
2020-08-28 |
Univ California |
Compositions and methods for treating neurodegenerative diseases and cardiomyopathy
|
KR20150119254A
(ko)
|
2013-02-15 |
2015-10-23 |
알러간, 인코포레이티드 |
지속된 약물 전달 임플란트
|
RS60026B1
(sr)
|
2013-02-18 |
2020-04-30 |
Vegenics Pty Ltd |
Molekuli koji vezuju ligande i njihove upotrebe
|
CA2940513C
(en)
|
2013-03-11 |
2023-08-15 |
University Of Florida Research Foundation, Inc. |
Delivery of card protein as therapy for ocular inflammation
|
US9890127B2
(en)
|
2013-03-11 |
2018-02-13 |
The Broad Institute, Inc. |
Compounds and compositions for the treatment of cancer
|
EP2967824B1
(en)
|
2013-03-12 |
2020-11-04 |
Carnegie Mellon University |
Coated vaso-occlusive device for treatment of aneurysms
|
US10245422B2
(en)
|
2013-03-12 |
2019-04-02 |
Corium International, Inc. |
Microprojection applicators and methods of use
|
WO2014159060A1
(en)
|
2013-03-14 |
2014-10-02 |
Hallux, Inc. |
Method of treating infections, diseases or disorders of nail unit
|
CN105246458B
(zh)
|
2013-03-15 |
2020-09-15 |
考里安公司 |
用于治疗剂递送的微阵列及其使用方法
|
US10308687B2
(en)
|
2013-03-15 |
2019-06-04 |
Apellis Pharmaceuticals, Inc. |
Cell-penetrating compstatin analogs and uses thereof
|
WO2014151769A1
(en)
|
2013-03-15 |
2014-09-25 |
Allergan, Inc. |
Compositions including encapsulated isotretinoin and methods for use thereof
|
US10517759B2
(en)
|
2013-03-15 |
2019-12-31 |
Glaukos Corporation |
Glaucoma stent and methods thereof for glaucoma treatment
|
EP2994758B1
(en)
|
2013-05-08 |
2017-12-20 |
Opthea Limited |
Biomarkers for age-related macular degeneration (amd)
|
KR102373982B1
(ko)
|
2013-08-21 |
2022-03-14 |
센세오닉스, 인코포레이티드 |
생-감지 분석물의 생체 내 보호를 위한 약물 용출
|
JP6543431B2
(ja)
*
|
2013-10-10 |
2019-07-10 |
ユニバーシティー オブ ユタ リサーチ ファウンデーションUniversity of Utah Research Foundation |
眼内薬物送達デバイスおよび付随する方法
|
WO2015116709A1
(en)
|
2014-01-28 |
2015-08-06 |
Allergan, Inc. |
Topical retinoid formulations and methods of use
|
EP3104706B1
(en)
|
2014-02-11 |
2022-03-23 |
Mitokinin, Inc. |
Compositions and methods using the same for treatment of neurodegenerative and mitochondrial disease
|
EP3132804B1
(en)
|
2014-04-17 |
2021-05-05 |
Seed Co., Ltd. |
Medical device including anionic drug
|
WO2015184173A1
(en)
|
2014-05-29 |
2015-12-03 |
Dose Medical Corporation |
Implants with controlled drug delivery features and methods of using same
|
WO2016005599A1
(en)
|
2014-07-10 |
2016-01-14 |
Biocopea Limited |
Compositions, methods and uses for treating gender-biased immune disorders
|
WO2016036866A1
(en)
|
2014-09-04 |
2016-03-10 |
Corium International, Inc. |
Microstructure array, methods of making, and methods of use
|
WO2016144832A1
(en)
|
2015-03-06 |
2016-09-15 |
Envisia Therapeutics, Inc. |
Implant applicators and methods of administering implants
|
WO2017004067A1
(en)
|
2015-06-29 |
2017-01-05 |
Corium International, Inc. |
Microarray for delivery of therapeutic agent, methods of use, and methods of making
|
EP3324944A4
(en)
|
2015-07-23 |
2019-04-03 |
Aerie Pharmaceuticals, Inc. |
INTRAVITREAL AGGREGATION SYSTEMS FOR THE TREATMENT OF EYE DISEASE
|
ES2828694T3
(es)
|
2015-07-29 |
2021-05-27 |
Allergan Inc |
Anticuerpos sólo de cadena pesada frente a ANG-2
|
US10308711B2
(en)
|
2015-08-14 |
2019-06-04 |
Allergan, Inc. |
Heavy chain only antibodies to PDGF
|
US11925578B2
(en)
|
2015-09-02 |
2024-03-12 |
Glaukos Corporation |
Drug delivery implants with bi-directional delivery capacity
|
MA43313B1
(fr)
|
2015-09-02 |
2022-06-30 |
Trevena Inc |
Aza-hétérocyclique à 6 éléments contenant des composés modulateurs de récepteurs opioïdes delta, et leurs procédés de fabrication et d'utilisation
|
US11564833B2
(en)
|
2015-09-25 |
2023-01-31 |
Glaukos Corporation |
Punctal implants with controlled drug delivery features and methods of using same
|
CN117503905A
(zh)
|
2015-10-07 |
2024-02-06 |
阿佩利斯制药有限公司 |
给药方案
|
EP3362095B1
(en)
|
2015-10-13 |
2020-11-25 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment of choroidal neovascularisation
|
EP4088719A1
(en)
|
2015-10-13 |
2022-11-16 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Methods and pharmaceutical compositions for the treatment of retinal capillary non-perfusion
|
WO2017064119A1
(en)
|
2015-10-13 |
2017-04-20 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment of retinal capillary non-perfusion
|
AU2016344018B2
(en)
|
2015-10-31 |
2019-02-28 |
Io Therapeutics, Inc. |
Treatment of nervous system disorders using combinations of RXR agonists and thyroid hormones
|
PT109154B
(pt)
*
|
2016-02-12 |
2019-11-05 |
Univ De Coimbra |
Tecnologia não-invasiva de inserto ocular para libertação controlada de fármacos
|
IL261669B2
(en)
|
2016-03-10 |
2023-12-01 |
Io Therapeutics Inc |
A combination of thyroid hormones and an RXR agonist for the treatment of autoimmune diseases
|
WO2017155578A1
(en)
|
2016-03-10 |
2017-09-14 |
Io Therapeutics, Inc. |
Treatment of muscular disorders with combinations of rxr agonists and thyroid hormones
|
WO2017173327A1
(en)
|
2016-03-31 |
2017-10-05 |
The Schepens Eye Research Institute, Inc. |
Endomucin inhibitor as an anti-angiogenic agent
|
US20190125669A1
(en)
*
|
2016-04-17 |
2019-05-02 |
Children's Medical Center Corporation |
Systems and methods for steroidal gels
|
EP3442479A1
(en)
|
2016-04-20 |
2019-02-20 |
Harold Alexander Heitzmann |
Bioresorbable ocular drug delivery device
|
MX2019000050A
(es)
|
2016-07-05 |
2019-05-02 |
Janssen Biotech Inc |
Tratamiento de la enfermedad vascular retinal mediante el uso de celulas progenitoras.
|
EP3484463B1
(en)
|
2016-08-19 |
2020-02-12 |
The United States of America, as Represented by The Secretary, Department of Health and Human Services Office of Technology Transfer |
Selective estrogen-receptor modulators (serms) confer protection against photoreceptor degeneration
|
WO2018093797A1
(en)
|
2016-11-15 |
2018-05-24 |
The Schepens Eye Research Institute, Inc. |
Compositions and methods for the treatment of aberrant angiogenesis
|
BR112019016775A2
(pt)
|
2017-02-17 |
2020-03-31 |
Trevena, Inc. |
Compostos moduladores de receptor delta-opioide contendo aza-heterocíclico com 7 membros, métodos de uso e produção dos mesmos
|
KR20190129867A
(ko)
|
2017-02-17 |
2019-11-20 |
트레베나, 인코포레이티드. |
5-원 아자-헤테로고리 함유 델타-오피오이드 수용체 조절 화합물, 및 그의 사용 및 제조 방법
|
CA3059304A1
(en)
|
2017-04-07 |
2018-10-11 |
Apellis Pharmaceuticals, Inc. |
Dosing regimens and related compositions and methods
|
EP3618841B1
(en)
|
2017-05-05 |
2023-03-22 |
University of Pittsburgh - of The Commonwealth System of Higher Education |
Ocular applications of matrix bound vesicles (mbvs)
|
US20190224275A1
(en)
|
2017-05-12 |
2019-07-25 |
Aurinia Pharmaceuticals Inc. |
Protocol for treatment of lupus nephritis
|
WO2018237145A1
(en)
|
2017-06-21 |
2018-12-27 |
Mitokinin, Inc. |
COMPOSITIONS AND METHODS USING THEM FOR THE TREATMENT OF NEURODEGENERATIVE AND MITOCHONDRIAL DISEASE
|
CA3072673A1
(en)
|
2017-08-11 |
2019-02-14 |
Unity Biotechnology, Inc. |
Treatment of ophthalmic conditions such as macular degeneration, glaucoma, and diabetic retinopathy using pharmaceutical agents that eliminate senescent cells
|
CA3076373A1
(en)
|
2017-09-20 |
2019-03-28 |
Io Therapeutics, Inc. |
Treatment of disease with esters of selective rxr agonists
|
WO2019070917A1
(en)
|
2017-10-03 |
2019-04-11 |
The Schepens Eye Research Institute, Inc. |
COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE DEGENERATION OF RETINAL PIGMENT EPITHELIUM AND METHODS USING SAME
|
US20220104839A1
(en)
|
2017-10-16 |
2022-04-07 |
Retriever Medical, Inc. |
Clot Removal Methods and Devices with Multiple Independently Controllable Elements
|
AU2021362245A1
(en)
|
2017-10-16 |
2023-05-25 |
Retriever Medical, Inc. |
Clot removal methods and devices with multiple independently controllable elements
|
US10258357B1
(en)
|
2017-10-16 |
2019-04-16 |
Michael Bruce Horowitz |
Catheter based retrieval device with proximal body having axial freedom of movement
|
AU2018369784B2
(en)
|
2017-11-14 |
2023-06-01 |
Massachusetts Eye And Ear Infirmary |
RUNX1 inhibition for treatment of proliferative vitreoretinopathy and conditions associated with epithelial to mesenchymal transition
|
US20210009651A1
(en)
|
2018-03-02 |
2021-01-14 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Se |
Use of il-34 to treat retinal inflammation and neurodegeneration
|
BR112020022083A2
(pt)
*
|
2018-05-01 |
2021-02-02 |
Chibi, Inc. |
depot líquido, estojo e método para tratar a retina.
|
US11672860B2
(en)
|
2018-11-02 |
2023-06-13 |
Senseonics, Incorporated |
Drug eluting matrix on analyte indicator
|
US10966950B2
(en)
|
2019-06-11 |
2021-04-06 |
Io Therapeutics, Inc. |
Use of an RXR agonist in treating HER2+ cancers
|
US11471426B2
(en)
|
2019-10-16 |
2022-10-18 |
American River Nutrition, Llc |
Compositions comprising quinone and/or quinol and methods of preparations and use thereof
|
CA3165922A1
(en)
|
2020-01-17 |
2021-07-22 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Gene therapy for treatment of crx-autosomal dominant retinopathies
|
WO2021244964A1
(en)
|
2020-06-01 |
2021-12-09 |
Black Cat Bio Limited |
Compositions and methods for treating infections and netopathy
|
WO2023105417A1
(en)
|
2021-12-06 |
2023-06-15 |
Breye Therapeutics Aps |
Danegaptide formulation for applicatoin in the eye
|
WO2023108012A1
(en)
|
2021-12-07 |
2023-06-15 |
Io Therapeutics, Inc. |
Use of an rxr agonist and taxanes in treating her2+ cancers
|
US11779553B1
(en)
*
|
2022-11-28 |
2023-10-10 |
Atif B. D. Collins |
Methods and devices for treatment of eyelid ptosis
|